11-11/12 :: November/December 2011

nanotimes

Companies Facts

the only source that met the Navy’s requirements. The system provides in-situ analysis for recipe de- velopment, via mass spectrometry and residual gas analysis.

http://www.aldnanosolutions.com/

proved a quarterly cash dividend of $0.08 per share payable on the company‘s common stock. The divi- dend is payable on March 15, 2012 to stockholders of record as of February 23, 2012.

A

Furthermore, Applied Materials extends its leadership in defect review SEM technology with the launch of its Applied SEMVision™ G5 system – the first tool that enables chipmakers to image and analyze 20nm yield-limiting defects in a production environment without manual intervention. Uniquely capable of identifying and imaging relevant defects with 1nm pixel size, the SEMVision G5 system allows logic and memory customers to streamline manufacturing, pinpointing the root cause of defects faster and more accurately than ever before.

Moreover, the Company announced its new Applied Producer®

Optiva™ CVD system that enables the

manufacture of state-of-the-art, backside-illuminated (BSI) image sensors used in the most advanced smart- phones, tablet PCs and high-end cameras.

http://www.appliedmaterials.com

pplied Materials, Inc. (NASDAQ: AMAT) announced that its Board of Directors has ap-

EP1976431B1, for its EZKnowz™, a multiple-gas bre- ath sensor for use in medical applications for the de- tection of potential disease states. This patent covers the complete EZKnowz™ sensor platform, including a sample collector, analysis device and data storage device. The EZKnowz™ sensor platform, developed by Applied Nanotech, combines existing differential ion mobility spectrometry technology with Applied Nanotech’s proprietary non-radioactive ion source.

A

Moreover, Applied Nanotech has hired Dr. Royce Johnson to accelerate its business development initia- tives in medical sectors.

http://www.appliednanotech.net

1-for-10 reverse stock split of its common stock. Trading on a post-split basis began on November 17, 2011. The reverse stock split was proposed by the Company’s Board of Directors and approved by Arrowhead stockholders at the 2011 Annual Meeting of Shareholders held on August 8, 2011. Moreover, Arrowhead Research has appointed David Lewis, Ph.D., as Vice President, Biology, and David Rozema, Ph.D., as Vice President, Chemistry, effec- tive immediately. Drs. Lewis and Rozema hold a long history with the Madison facility, formerly owned by Roche, as the Site Head and Director of Research and Program Director of Delivery Chemistry, respec- tively, since 2008.

A http://www.arrowheadresearch.com

rrowhead Research Corporation (NASDAQ: ARWR) announced the implementation of a

pplied Nanotech Holdings, Inc. (OTC BB: APNT) has been awarded European Patent

13